Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10024960 | 1.00 | DPP4 (0.65) | DPP4ADRA2AADRA2CF2LMNA | |
| SCHEMBL21588545 | 1.00 | DPP4 (0.65) | DPP4ADRA2AADRA2CF2LMNA | |
| SCHEMBL14299183 | 1.00 | DPP4 (0.65) | DPP4ADRA2AADRA2CF2LMNA | |
| SCHEMBL17108646 | 1.00 | DPP4 (0.65) | DPP4ADRA2AADRA2CF2LMNA | |
| SCHEMBL15043425 | 1.00 | DPP4 (0.65) | DPP4ADRA2AADRA2CF2LMNA | |
| Hydrochloric Acid SCHEMBL7266794 | 0.97 | DPP4 (0.62) | DPP4ADRA2AADRA2CF2LMNA | |
| SCHEMBL5308340 | 0.89 | DPP4 (0.52) | DPP4ADRA2AADRA2CF2LMNA | |
| SCHEMBL2893631 | 0.89 | DPP4 (0.52) | DPP4ADRA2AADRA2CF2LMNA | |
| SCHEMBL8867126 | 0.87 | ADRB2 (0.54) | DPP4ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL8866154 | 0.87 | DPP4 (0.50) | DPP4ADRA2AADRA2CF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107530415-A | For activating the composition and method of the conduction of \" interferon gene stimulant \" dependent signals | 艾杜罗生物科技公司 | 2018-01-02 | — | — | CN | claimed |
| CN-104081469-A | Electrically insulating oil composition having excellent performance in wide temperature range | JX NIPPON OIL & ENERGY CORP | 2014-10-01 | — | — | CN | claimed |
| CN-103582920-A | Electrical insulating oil composition having excellent low-temperature characteristics | JX NIPPON OIL & ENERGY CORP | 2014-02-12 | — | — | CN | claimed |
| WO-2007017652-A2 | ARYLAKYLAMINES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| CN-1652695-A | Method for improving growth performance of animals | UNIV SYDNEY (AU) | 2005-08-10 | — | — | CN | claimed |
| EP-0356035-B1 | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties | ASTRA AB (SE) | 1996-03-13 | — | — | EP | claimed |
| WO-1995031986-A1 | COMBINATION PRODUCT OF DICHLOROACETIC ACID AND AN NMDA ANTAGONIST | ASTRA AKTIEBOLAG (SE) | 1995-11-30 | — | — | WO | claimed |
| US-5430044-A | Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties | FISONS CORPORATION (GB) | 1995-07-04 | — | — | US | claimed |
| US-4902707-A | Bicyclic pyrazolidinones, compositions and use | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | claimed |
| US-4631339-A | 1,3,5-triazepinones | ELI LILLY AND COMPANY (US) | 1986-12-23 | — | — | US | claimed |
| US-4563523-A | INTERMEDIATES FOR CEFTAZIDIME AND CEPHALORIDINE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 1986-01-07 | — | — | US | claimed |
| US-12630501-B2 | Anti-fibrotic compounds and use thereof | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2026-05-19 | — | — | US | disclosed |
| EP-4727917-A1 | BIODEGRADABLE CARBAMATE LIPIDS WITH INCREASED STABILITY | Ramot at Tel-Aviv University Ltd. (IL) | 2026-04-22 | — | — | EP | disclosed |
| US-12605422-B2 | Compositions and methods for treating degenerative, age-related and trauma-induced disorders | S.I.S SHULOV INNOVATIVE SCIENCE LTD. (IL) | 2026-04-21 | — | — | US | disclosed |
| US-20260102386-A1 | USE OF HEXOKINASE 2/MITOCHONDRIA-DETACHING COMPOUNDS FOR TREATING HEXOKINASE-2 (HK2)-EXPRESSING CANCERS | VIDAC PHARMA LTD. (IL) | 2026-04-16 | — | — | US | disclosed |
| US-4138555-A | BACTERICIDES | GLAXO LABORATORIES, LIMITED (GB) | 1979-02-06 | — | — | US | disclosed |
| US-4122259-A | 7β-[2-Aryl-2-(etherified oximino)acetamido]-3-N-substituted carbamoyloxymethylceph-3-em-4-carboxylic acids | GLAXO LABORATORIES LIMITED (GB) | 1978-10-24 | — | — | US | disclosed |
| US-4103084-A | ANTIBIOTICS | GLAXO LABORATORIES LIMITED (GB) | 1978-07-25 | — | — | US | disclosed |
| US-4007174-A | Cephalosporin compounds | GLAXO LABORATORIES LIMITED (EN) | 1977-02-08 | — | — | US | disclosed |
| US-3936443-A | Penicillin antibiotics | GLAXO LABORATORIES LIMITED (EN) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605422-B2 | Compositions and methods for treating degenerative, age-related and trauma-induced disorders | HTT, MAPT, APP | DPP4 581/4885ADRA2A 3339/4885ADRA2C 3019/4885 |
| US-12630501-B2 | Anti-fibrotic compounds and use thereof | SIRT1, SIRT2, SIRT3 | DPP4 2843/4885ADRA2A 558/4885ADRA2C 572/4885 |
| US-20260102386-A1 | USE OF HEXOKINASE 2/MITOCHONDRIA-DETACHING COMPOUNDS FOR TREATING HEXOKINASE-2 (HK2)-EXPRESSING CANCERS | HK2, HK1, AK2 | DPP4 2684/4885ADRA2A 3021/4885ADRA2C 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.